Evidence map›Paper›PMID 35621629›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.

Sarka Nemeckova, Kamila Alexova-Zurkova, Petr Hainz, Jitka Krystofova, Jana Mackova, Katerina Roubalova, Marketa Stastna-Markova, Milena Vrana, Jan Vydra

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sarka NemeckovaInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.ORCID 0000-0001-6001-4007
Kamila Alexova-ZurkovaInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.ORCID 0000-0003-0999-880X
Petr HainzInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.
Jitka KrystofovaInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.
Jana MackovaInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.
Katerina RoubalovaInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.
Marketa Stastna-MarkovaInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.
Milena VranaInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.ORCID 0000-0002-6905-6227
Jan VydraInstitute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.
Institute of Haematology and Blood Transfusion · CZCharles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein expressed in all tissues. The protein is mainly localized in nucleoli. In hematological malignancies,

Indexed as

Leukemia, Myeloid, AcuteNucleophosminCD8-Positive T-LymphocytesHematopoietic Stem CellsHumansNuclear ProteinsNuclear ProteinsNucleophosminacute myeloid leukemiahematopoietic stem cell transplantationmutationnucleophosmin 1T cell response

Identifiers

PMID35621629
PMCPMC9140185
OpenAlexW4224228473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.